Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study.

Kategorie Primary study
ZeitungThe American journal of psychiatry
Year 1999
Loading references information
Determined the efficacy of fluvoxamine for the treatment of social phobia (social anxiety disorder). In a 12-wk multicenter, double-blind, randomized, placebo-controlled trial, 92 patients (mean age 39.1 yrs) with social phobia were treated with the selective serotonin reuptake inhibitor fluvoxamine (202 mg); 91.3% of the patients had the generalized subtype of the disorder. The primary criterion for response was a rating of "much improved" or "very much improved" on the Clinical Global Impression of Improvement scale. Secondary response criteria were changes on 3 specialized rating scales for social phobia symptoms: the Brief Social Phobia Scale, the Social Phobia Inventory, and the Liebowitz Social Anxiety Scale. Psychosocial impairment was assessed in disruption of work, social life, and home/family life. At study end or with the last observation carried forward, within the 86 evaluable Ss there was a significantly higher proportion of responders in the fluvoxamine group than in the placebo group. Similarly, fluvoxamine was superior to placebo on all social phobia rating scales at week 8 and beyond. Fluvoxamine also resulted in significantly greater decreases in measures of psychosocial disability than did placebo. Overall, fluvoxamine was well tolerated and safe. (PsycInfo Database Record (c) 2021 APA, all rights reserved)
Epistemonikos ID: 71f68e695aa132f71fecc1ce6fa22c3f8d85be34
First added on: Dec 31, 2012